Because ASCO guideline updates [18], and ESMO consensus statements [19] indicate that adjuvant osimertinib is recommended for NSCLC patients with an EGFR sensitizing mutation regardless of the PD-L1 expression status, the ultra-rapid Idylla EGFR Mutation Test will provide a potential to avoid unessential PD-L1 testing if the examined specimen had an EGFR-sensitizing mutation. Here, EGFR is linked to non-small cell lung carcinoma.